Il n'y a pas d'antidote spécifique, mais des traitements symptomatiques sont disponibles.
Réactions allergiquesTraitementUrgence médicale
#3
Peut-on prendre des analgésiques après la vaccination ?
Oui, des analgésiques comme le paracétamol peuvent être pris pour soulager la douleur.
AnalgésiquesEffets indésirablesVaccins
#4
Comment gérer la fièvre post-vaccination ?
Hydratez-vous et reposez-vous, des antipyrétiques peuvent aider à réduire la fièvre.
FièvreTraitementVaccins
#5
Les traitements sont-ils différents pour les jeunes ?
Les traitements sont généralement similaires, mais les doses peuvent varier selon l'âge.
ÂgeTraitementVaccins
Complications
5
#1
Quelles sont les complications possibles du vaccin ?
Des complications rares incluent des thromboses et des réactions allergiques sévères.
ComplicationsEffets indésirablesVaccins
#2
Comment gérer une thrombose post-vaccination ?
Consultez immédiatement un médecin si vous ressentez des douleurs ou des gonflements.
ThromboseUrgence médicaleVaccins
#3
Les complications sont-elles plus fréquentes chez certains groupes ?
Oui, les personnes avec des antécédents de thrombose peuvent être à risque accru.
Facteurs de risqueThromboseVaccins
#4
Y a-t-il un suivi après des complications ?
Oui, un suivi médical est recommandé pour surveiller les complications éventuelles.
Suivi médicalComplicationsVaccins
#5
Les complications sont-elles signalées ?
Oui, les effets indésirables sont signalés aux autorités sanitaires pour évaluation.
SurveillanceEffets indésirablesVaccins
Facteurs de risque
5
#1
Qui est à risque accru de complications ?
Les personnes avec des antécédents médicaux comme des troubles de la coagulation.
Facteurs de risqueComplicationsSanté
#2
Les personnes âgées doivent-elles être plus prudentes ?
Oui, les personnes âgées peuvent avoir un risque accru de complications post-vaccinales.
ÂgeComplicationsVaccins
#3
Les allergies affectent-elles la vaccination ?
Les personnes avec des allergies sévères doivent consulter un médecin avant la vaccination.
AllergiesVaccinsConsultation médicale
#4
Les maladies chroniques influencent-elles la vaccination ?
Oui, certaines maladies chroniques peuvent augmenter le risque de complications.
Maladies chroniquesFacteurs de risqueVaccins
#5
Les antécédents de thrombose sont-ils un facteur de risque ?
Oui, les antécédents de thrombose peuvent augmenter le risque de complications.
ThromboseFacteurs de risqueVaccins
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vaccin ChAdOx1 nCoV-19 : Questions médicales les plus fréquentes",
"headline": "Vaccin ChAdOx1 nCoV-19 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vaccin ChAdOx1 nCoV-19 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-10",
"dateModified": "2026-01-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vaccin ChAdOx1 nCoV-19"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vaccins contre la COVID-19",
"url": "https://questionsmedicales.fr/mesh/D000086663",
"about": {
"@type": "MedicalCondition",
"name": "Vaccins contre la COVID-19",
"code": {
"@type": "MedicalCode",
"code": "D000086663",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215.894.899.085"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vaccin ChAdOx1 nCoV-19",
"alternateName": "ChAdOx1 nCoV-19",
"code": {
"@type": "MedicalCode",
"code": "D000090985",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Teresa Lambe",
"url": "https://questionsmedicales.fr/author/Teresa%20Lambe",
"affiliation": {
"@type": "Organization",
"name": "The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Sarah C Gilbert",
"url": "https://questionsmedicales.fr/author/Sarah%20C%20Gilbert",
"affiliation": {
"@type": "Organization",
"name": "The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom."
}
},
{
"@type": "Person",
"name": "Elizabeth J Kelly",
"url": "https://questionsmedicales.fr/author/Elizabeth%20J%20Kelly",
"affiliation": {
"@type": "Organization",
"name": "From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York - all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), the University of Maryland School of Medicine (K.M.N.) and the Johns Hopkins Bloomberg School of Public Health (A.D.), Baltimore, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, Edgewood (J.C.), and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (T. Tong, M.B.I., M.C.N.) - all in Maryland; the University of Washington (L.C., W.H.) and the Fred Hutchinson Cancer Research Center (L.C., W.H., J.H., H.E.J.), Seattle; HealthPartners Institute, St. Paul, MN (C.M.); Orlando Immunology Center, Orlando (E.D.), and JEM Headlands Research, Lake Worth Beach (L.B.) - both in Florida; Hassman Research Institute, Berlin, NJ (M.H.); the University of California San Diego, La Jolla (S.J.L.), the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.S.D.), and the San Francisco Department of Public Health, San Francisco (S.B.) - all in California; Children's Mercy Kansas City, Kansas City, MO (B.A.P.); Tekton Research, Austin (P.P.), and Centex Studies, McAllen (J.S.) - both in Texas; Medpharmics, Albuquerque, NM (Q.O.C.); John H. Stroger, Jr. Hospital of Cook County, Chicago (T.O.); Instituto de Ciencias Biomédicas, Facultad de Medicina Universidad de Chile, Santiago, Chile (S.L.V.); Clínica Internacional Sede Lima, Lima, Peru (A.G.B.); Clinical Research Partners, Richmond, VA (R.C.); the University of Vermont Larner College of Medicine and UVM Medical Center, Burlington (B.D.K.); Mercury Street Medical Group, Butte, MT (J.P.); and the Rollins School of Public Health at Emory University, Atlanta (D.B.)."
}
},
{
"@type": "Person",
"name": "Sandra Belij-Rammerstorfer",
"url": "https://questionsmedicales.fr/author/Sandra%20Belij-Rammerstorfer",
"affiliation": {
"@type": "Organization",
"name": "Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36855108",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12916-023-02795-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Inflammatory and cytotoxic mediators in COVID-19 patients and in ChAdOx1 nCoV-19 (AZD1222) vaccine recipients.",
"datePublished": "2023-09-04",
"url": "https://questionsmedicales.fr/article/37672863",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cyto.2023.156350"
}
},
{
"@type": "ScholarlyArticle",
"name": "Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.",
"datePublished": "2023-02-10",
"url": "https://questionsmedicales.fr/article/36775731",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jfo.2022.09.017"
}
},
{
"@type": "ScholarlyArticle",
"name": "ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37322179",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41590-023-01513-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Thrombosis with Thrombocytopenia Syndrome (TTS) After ChAdOx1 nCoV-19 Immunization: An Investigative Case Report.",
"datePublished": "2023-03-18",
"url": "https://questionsmedicales.fr/article/36932639",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12659/AJCR.938878"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Mélanges complexes",
"item": "https://questionsmedicales.fr/mesh/D045424"
},
{
"@type": "ListItem",
"position": 3,
"name": "Produits biologiques",
"item": "https://questionsmedicales.fr/mesh/D001688"
},
{
"@type": "ListItem",
"position": 4,
"name": "Vaccins",
"item": "https://questionsmedicales.fr/mesh/D014612"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vaccins antiviraux",
"item": "https://questionsmedicales.fr/mesh/D014765"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vaccins contre la COVID-19",
"item": "https://questionsmedicales.fr/mesh/D000086663"
},
{
"@type": "ListItem",
"position": 7,
"name": "Vaccin ChAdOx1 nCoV-19",
"item": "https://questionsmedicales.fr/mesh/D000090985"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vaccin ChAdOx1 nCoV-19 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vaccin ChAdOx1 nCoV-19",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vaccin ChAdOx1 nCoV-19",
"description": "Comment savoir si le vaccin est efficace ?\nQuels tests sont utilisés pour évaluer l'immunité ?\nQuand faire un test après la vaccination ?\nPeut-on être infecté après la vaccination ?\nComment surveiller les effets secondaires ?",
"url": "https://questionsmedicales.fr/mesh/D000090985#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vaccin ChAdOx1 nCoV-19",
"description": "Quels sont les effets secondaires courants ?\nLes symptômes graves sont-ils fréquents ?\nCombien de temps durent les effets secondaires ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D000090985#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vaccin ChAdOx1 nCoV-19",
"description": "Le vaccin prévient-il toutes les formes de COVID-19 ?\nFaut-il continuer à porter un masque après la vaccination ?\nQuand est-on protégé après la vaccination ?\nLe vaccin est-il sûr pour les femmes enceintes ?\nComment se préparer à la vaccination ?",
"url": "https://questionsmedicales.fr/mesh/D000090985#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vaccin ChAdOx1 nCoV-19",
"description": "Que faire en cas d'effets secondaires ?\nY a-t-il un antidote pour les réactions graves ?\nPeut-on prendre des analgésiques après la vaccination ?\nComment gérer la fièvre post-vaccination ?\nLes traitements sont-ils différents pour les jeunes ?",
"url": "https://questionsmedicales.fr/mesh/D000090985#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vaccin ChAdOx1 nCoV-19",
"description": "Quelles sont les complications possibles du vaccin ?\nComment gérer une thrombose post-vaccination ?\nLes complications sont-elles plus fréquentes chez certains groupes ?\nY a-t-il un suivi après des complications ?\nLes complications sont-elles signalées ?",
"url": "https://questionsmedicales.fr/mesh/D000090985#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vaccin ChAdOx1 nCoV-19",
"description": "Qui est à risque accru de complications ?\nLes personnes âgées doivent-elles être plus prudentes ?\nLes allergies affectent-elles la vaccination ?\nLes maladies chroniques influencent-elles la vaccination ?\nLes antécédents de thrombose sont-ils un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D000090985#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment savoir si le vaccin est efficace ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est mesurée par des études cliniques et des taux d'infection réduits."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'immunité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sérologiques mesurent les anticorps spécifiques contre le SARS-CoV-2."
}
},
{
"@type": "Question",
"name": "Quand faire un test après la vaccination ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est recommandé de faire un test 2 à 4 semaines après la deuxième dose."
}
},
{
"@type": "Question",
"name": "Peut-on être infecté après la vaccination ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vaccin réduit le risque mais ne garantit pas une protection totale."
}
},
{
"@type": "Question",
"name": "Comment surveiller les effets secondaires ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont surveillés par des rapports de patients et des études."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets incluent douleur au bras, fatigue, fièvre et maux de tête."
}
},
{
"@type": "Question",
"name": "Les symptômes graves sont-ils fréquents ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes graves sont rares, mais peuvent inclure des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Combien de temps durent les effets secondaires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des effets secondaires disparaissent en quelques jours."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez des symptômes comme des éruptions cutanées ou des difficultés respiratoires."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes peuvent avoir des effets différents par rapport aux personnes âgées."
}
},
{
"@type": "Question",
"name": "Le vaccin prévient-il toutes les formes de COVID-19 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le vaccin réduit le risque d'infection, mais ne prévient pas toutes les variantes."
}
},
{
"@type": "Question",
"name": "Faut-il continuer à porter un masque après la vaccination ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est conseillé de porter un masque dans les lieux à haut risque."
}
},
{
"@type": "Question",
"name": "Quand est-on protégé après la vaccination ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La protection maximale est atteinte environ deux semaines après la deuxième dose."
}
},
{
"@type": "Question",
"name": "Le vaccin est-il sûr pour les femmes enceintes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que le vaccin est généralement sûr pour les femmes enceintes."
}
},
{
"@type": "Question",
"name": "Comment se préparer à la vaccination ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Hydratez-vous, reposez-vous bien et informez-vous sur les effets secondaires possibles."
}
},
{
"@type": "Question",
"name": "Que faire en cas d'effets secondaires ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez un médecin si les effets secondaires persistent ou s'aggravent."
}
},
{
"@type": "Question",
"name": "Y a-t-il un antidote pour les réactions graves ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas d'antidote spécifique, mais des traitements symptomatiques sont disponibles."
}
},
{
"@type": "Question",
"name": "Peut-on prendre des analgésiques après la vaccination ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des analgésiques comme le paracétamol peuvent être pris pour soulager la douleur."
}
},
{
"@type": "Question",
"name": "Comment gérer la fièvre post-vaccination ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Hydratez-vous et reposez-vous, des antipyrétiques peuvent aider à réduire la fièvre."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents pour les jeunes ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements sont généralement similaires, mais les doses peuvent varier selon l'âge."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du vaccin ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications rares incluent des thromboses et des réactions allergiques sévères."
}
},
{
"@type": "Question",
"name": "Comment gérer une thrombose post-vaccination ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez immédiatement un médecin si vous ressentez des douleurs ou des gonflements."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles plus fréquentes chez certains groupes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des antécédents de thrombose peuvent être à risque accru."
}
},
{
"@type": "Question",
"name": "Y a-t-il un suivi après des complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical est recommandé pour surveiller les complications éventuelles."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles signalées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les effets indésirables sont signalés aux autorités sanitaires pour évaluation."
}
},
{
"@type": "Question",
"name": "Qui est à risque accru de complications ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec des antécédents médicaux comme des troubles de la coagulation."
}
},
{
"@type": "Question",
"name": "Les personnes âgées doivent-elles être plus prudentes ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir un risque accru de complications post-vaccinales."
}
},
{
"@type": "Question",
"name": "Les allergies affectent-elles la vaccination ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec des allergies sévères doivent consulter un médecin avant la vaccination."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques influencent-elles la vaccination ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies chroniques peuvent augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Les antécédents de thrombose sont-ils un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de thrombose peuvent augmenter le risque de complications."
}
}
]
}
]
}
From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York - all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), the University of Maryland School of Medicine (K.M.N.) and the Johns Hopkins Bloomberg School of Public Health (A.D.), Baltimore, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, Edgewood (J.C.), and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (T. Tong, M.B.I., M.C.N.) - all in Maryland; the University of Washington (L.C., W.H.) and the Fred Hutchinson Cancer Research Center (L.C., W.H., J.H., H.E.J.), Seattle; HealthPartners Institute, St. Paul, MN (C.M.); Orlando Immunology Center, Orlando (E.D.), and JEM Headlands Research, Lake Worth Beach (L.B.) - both in Florida; Hassman Research Institute, Berlin, NJ (M.H.); the University of California San Diego, La Jolla (S.J.L.), the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.S.D.), and the San Francisco Department of Public Health, San Francisco (S.B.) - all in California; Children's Mercy Kansas City, Kansas City, MO (B.A.P.); Tekton Research, Austin (P.P.), and Centex Studies, McAllen (J.S.) - both in Texas; Medpharmics, Albuquerque, NM (Q.O.C.); John H. Stroger, Jr. Hospital of Cook County, Chicago (T.O.); Instituto de Ciencias Biomédicas, Facultad de Medicina Universidad de Chile, Santiago, Chile (S.L.V.); Clínica Internacional Sede Lima, Lima, Peru (A.G.B.); Clinical Research Partners, Richmond, VA (R.C.); the University of Vermont Larner College of Medicine and UVM Medical Center, Burlington (B.D.K.); Mercury Street Medical Group, Butte, MT (J.P.); and the Rollins School of Public Health at Emory University, Atlanta (D.B.).
Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, UK.
Oxford Vaccine Group, Medical Sciences Division, Department of Paediatrics, University of Oxford and Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York - all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), the University of Maryland School of Medicine (K.M.N.) and the Johns Hopkins Bloomberg School of Public Health (A.D.), Baltimore, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, Edgewood (J.C.), and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (T. Tong, M.B.I., M.C.N.) - all in Maryland; the University of Washington (L.C., W.H.) and the Fred Hutchinson Cancer Research Center (L.C., W.H., J.H., H.E.J.), Seattle; HealthPartners Institute, St. Paul, MN (C.M.); Orlando Immunology Center, Orlando (E.D.), and JEM Headlands Research, Lake Worth Beach (L.B.) - both in Florida; Hassman Research Institute, Berlin, NJ (M.H.); the University of California San Diego, La Jolla (S.J.L.), the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.S.D.), and the San Francisco Department of Public Health, San Francisco (S.B.) - all in California; Children's Mercy Kansas City, Kansas City, MO (B.A.P.); Tekton Research, Austin (P.P.), and Centex Studies, McAllen (J.S.) - both in Texas; Medpharmics, Albuquerque, NM (Q.O.C.); John H. Stroger, Jr. Hospital of Cook County, Chicago (T.O.); Instituto de Ciencias Biomédicas, Facultad de Medicina Universidad de Chile, Santiago, Chile (S.L.V.); Clínica Internacional Sede Lima, Lima, Peru (A.G.B.); Clinical Research Partners, Richmond, VA (R.C.); the University of Vermont Larner College of Medicine and UVM Medical Center, Burlington (B.D.K.); Mercury Street Medical Group, Butte, MT (J.P.); and the Rollins School of Public Health at Emory University, Atlanta (D.B.).
Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA. neeltje.vandoremalen@nih.gov.
Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA. vincent.munster@nih.gov.
Both BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines have shown high efficacy against COVID-19 in randomized controlled trials. However, their comparative effectiveness ag...
We emulated a target trial using IQVIA Medical Research Database (IMRD), an electronic primary care database from the UK (2021). We included 1,311,075 participants, consisting of 637,549 men and 673,5...
During a mean of 6.7 months of follow-up, 20,070 confirmed SARS-CoV-2 infection occurred in individuals who received BNT162b2 vaccine (PS weighted incidence rate: 3.65 per 1000 person-months), and 31,...
In this population-based study, the BNT162b2 vaccine appears to be more efficacious than the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection and hospitalisation for COVID-19 but not death from CO...
Immunological and cytotoxic mediators are induced in natural infection and are essential for the effectiveness of vaccination. Vaccination is useful to prevent the spread of SARS-CoV-2 and limit the m...
Almost all vaccines have been reported to be associated with ocular inflammation, which has caused some concern regarding global mass COVID-19 vaccination efforts. Vogt-Koyanagi-Harada disease (VKHD) ...
Despite the success of COVID-19 vaccines, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern have emerged that can cause breakthrough infections. Although protection agai...
BACKGROUND Thrombosis with thrombocytopenia syndrome (TTS), including vaccine-induced immune thrombotic thrombocytopenia (VITT), is an extremely rare adverse effect, mostly seen after initial vaccinat...
To achieve global herd immunity, widespread vaccination is the most effective strategy. Vaccines stimulate the immune system, generating cytokines and chemokines, isotype antibodies, and neutralizing ...
This real-world study was conducted to assess the adverse effects following immunization (AEFI) and immunogenicity of ChAdO×1 nCoV-19 vaccine in terms of neutralising antibody titers and to study the ...
A total of 512 participants (M/F=274/238) aged 35(18-87) years comprising a mixed population of healthcare workers, other frontline workers and general public were enrolled between March and May 2021....
Incidence of local reactions was higher after first dose at 33.4 % (171/512) compared to those after second dose at 12.9 % (66/512). Commonest side effect observed was injection site pain after the fi...
The ChAdOx1 nCov-19 vaccine is apparently safe and effective against SARS-CoV-2 virus infection. Prior COVID infection and younger age group achieve higher antibody titers, but no additional protectio...
The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves u...
We assessed S-268019-b, a recombinant spike protein vaccine with a squalene-based adjuvant, for superiority in its immunogenicity over ChAdOx1 nCoV-19 vaccine among adults in Japan. In this multicente...